Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Creative Medical Technology Holdings, Inc. CELZ

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$6,000
▼ 45.5% YoY
$-6.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

In 2020, through our ImmCelz Inc. subsidiary, we began developing treatments under our ImmCelz™ platform (CELZ-100), that utilize a patient’s own extracted immune cells that are then “reprogrammed/supercharged” by culturing them outside the patient’s body with optimized cell-free factors. In June 2022, we signed an agreement with Greenstone Biosciences Inc. (“Greenstone”) for the development of a human induced pluripotent stem cell (iPSC) pipeline for our ImmCelz™ platform. In October 2022, we announced the development of our AlloStem™ Clinical Cell Line (CELZ-200), a proprietary allogenic cell line which includes a Master Cell Bank and a Drug Master File. In November 2022, we announced that the FDA had cleared the Company’s Type I Diabetes (CELZ-201 CREATE-1) Investigational New Drug (IND) application for the treatment of Type 1 Diabetes utilizing our AlloStem™ Clinical Cell Line, which will allow us to begin a Phase I/II clinical trial.

Written from the business description in Creative Medical Technology Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 20 March 2026. Every sentence was checked against that document before publication.

Growth

USD 6,000.00
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -6.0
10M20M-15M-30M
201020132016201920222025
Compound annual growth
−59.2%
−48.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −48.4% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -102380.2%
-50000%-100000%
201020172025
ROE
FY2025 · ROE -86.5%
-50%
201020172025
Three returns, three denominators.

Each USD of equity lost 87 cents this year.

Cash & shareholders

USD 0.00
returned in FY2025 · dividends + net buybacks
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks -7.2
-10M-20M
2022202320242025

Total assetsUSD 7.8M
EquityUSD 7.5M
CashUSD 7.2M
Current ratio25.97×

Equity funds 96% of total assets.

The 16-year record

16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
CELZ, 16-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Income tax $B0.00.00.00.00.00.00.00.00.00.00.0◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−2.52−3.71−3.76−0.935.61−62.69−0.82−3.50−0.03−0.010.000.000.000.000.000.00
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————————
ROE %−86.5−65.8−40.3−77.8————————————
Shares out B0.000.000.000.010.010.000.020.010.110.110.030.020.020.020.020.02

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 68 reconciliationsAUDITED

Reconciled in 16 of the 16 fiscal years we could check. Nine checks were skipped: cost of revenue is not tagged before 2016. Six checks were skipped: the balance sheet is not tagged before 2010. Four checks were skipped: the share count is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inNevada
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image